Becker's Healthcare November 19, 2024
Eli Lilly announced results from a Phase 2 trial of muvalapin, an experimental drug aimed at lowering lipoprotein(a), a genetically inherited form of cholesterol linked to heart disease.
The study, published in JAMA, showed that muvalapin lowered levels by up to 85.8% of adults with elevated levels of the lipid. In the trial, participants who received the highest dose of muvalapin showed the most significant reduction in lipoprotein(a) levels, compared to a...
Today's Sponsors
Today's Sponsor